Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Photodynamic therapy].

G Soubrane1, D Kuhn, H Oubraham

  • 1Clinique Ophtalmologique Universitaire de Créteil, Université Paris-XII, 40 avenue de Verdun, 94010 Créteil.

Journal Francais D'Ophtalmologie
|October 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: Alterations in circulating vasoactive substances in the critically ill-a comparison between survivors and non-survivors.

Intensive care medicine·2023
Same author

Retraction Note: Circulating adhesion molecules in the critically ill: A comparison between trauma and sepsis patients.

Intensive care medicine·2023
Same author

Laser-pump/X-ray-probe experiments with electrons ejected from a Cu(111) target: space-charge acceleration.

Journal of synchrotron radiation·2016
Same author

[Laryngeal and larynx-associated reflexes].

HNO·2016
Same author

[Diagnosis of auditory processing disorders in children].

HNO·2016
Same author

Abundant cytomegalovirus (CMV) reactive clonotypes in the CD8(+) T cell receptor alpha repertoire following allogeneic transplantation.

Clinical and experimental immunology·2016
Same journal

Silent threat to sight after bariatric surgery: Vision loss from vitamin A deficiency.

Journal francais d'ophtalmologie·2026
Same journal

Persistent subretinal fluid and subretinal precipitates following pneumatic retinopexy.

Journal francais d'ophtalmologie·2026
Same journal

Real-time documentation of acute pre-retinal hemorrhage in central retinal vein occlusion.

Journal francais d'ophtalmologie·2026
Same journal

Incidental detection of benign lobular inner nuclear layer proliferations (BLIPs) in a young adult.

Journal francais d'ophtalmologie·2026
Same journal

Combined autonomic and cranial neuropathy following radiofrequency ablation for trigeminal neuralgia.

Journal francais d'ophtalmologie·2026
Same journal

[Point-of-care biomarkers of ocular surface disease: Current approaches and future perspectives].

Journal francais d'ophtalmologie·2026
See all related articles

Photodynamic therapy using Verteporfin effectively treats subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD), preserving visual acuity. This treatment is particularly beneficial for patients with predominantly well-defined lesions.

Area of Science:

  • Ophthalmology
  • Medical Imaging
  • Pharmacology

Background:

  • Age-related macular degeneration (AMD) is a leading cause of vision loss.
  • Subfoveal choroidal neovascularization (CNV) is a common complication of AMD, leading to decreased visual acuity.
  • Photodynamic therapy (PDT) is an emerging treatment modality for CNV.

Purpose of the Study:

  • To evaluate the efficacy of Verteporfin (Visudyne) in treating subfoveal CNV secondary to AMD.
  • To assess the impact of PDT with Verteporfin on visual acuity and angiographic outcomes.
  • To compare the effectiveness of Verteporfin PDT against a placebo in patients with AMD-related CNV.

Main Methods:

  • Two international randomized clinical trials were conducted.
  • Patients with subfoveal CNV involving the macula and specific angiographic characteristics were included.

Related Experiment Videos

  • Participants were randomized to receive either Verteporfin PDT or a placebo in a 2:1 ratio.
  • Follow-up included visual acuity testing and fluorescein angiography for up to 3 months, with retreatment criteria based on leakage.

    • Main Results:

    • PDT with Verteporfin demonstrated significant efficacy compared to placebo in maintaining visual acuity.
    • Fewer treated patients experienced a decrease in visual acuity of 15 letters or more (61% vs. 46%).
    • Subgroup analysis showed superior outcomes in patients with predominantly well-defined CNV (67% vs. 39% preservation of visual acuity).
    • Verteporfin extravasation at the injection site was the most common side effect.

    Conclusions:

    • Photodynamic therapy with Verteporfin is an effective treatment for subfoveal CNV in AMD.
    • The treatment helps to limit visual acuity decrease, particularly in patients with well-defined lesions.
    • Verteporfin PDT represents a valuable therapeutic option for specific AMD patient populations.
    • Further investigation into managing side effects like extravasation may be warranted.